Jason Luke, Chief Medical Officer at Strand Therapeutics, shared a post on LinkedIn:
“Enjoyed this review on microRNAs regulating the tumor microenvironment.
At Strand Therapeutics our miRNA based SignalLock technology facilitates expansion of therapeutic index by de-targeting healthy organ tissues via physiologic miR binding, so that our replicating RNAs only translate in the TME. Amazing to consider all the ways that miR’s are increasingly impacting drug development!”
Title: Emerging role of microRNAs as modulators of the tumor immune microenvironment
Authors: Rachele Frigerio, Arianna Ortolano, Gennaro Ciliberto, Rita Mancini, Luigi Fattore.
Other articles about Strand Therapeutics on OncoDaily.